Genome-wide Association Analysis Identifies PDE4D as an Asthma-Susceptibility Gene  by Himes, Blanca E. et al.
ARTICLE
Genome-wide Association Analysis Identifies
PDE4D as an Asthma-Susceptibility Gene
Blanca E. Himes,1,2,3,4,* Gary M. Hunninghake,2 James W. Baurley,5 Nicholas M. Rafaels,6
Patrick Sleiman,7 David P. Strachan,8 Jemma B. Wilk,9 Saffron A.G. Willis-Owen,10
Barbara Klanderman,2 Jessica Lasky-Su,2 Ross Lazarus,2 Amy J. Murphy,2 Manuel E. Soto-Quiros,11
Lydiana Avila,11 Terri Beaty,6 Rasika A. Mathias,12 Ingo Ruczinski,6 Kathleen C. Barnes,6
Juan C. Celedo´n,2 William O.C. Cookson,10 W. James Gauderman,5 Frank D. Gilliland,5
Hakon Hakonarson,7 Christoph Lange,2 Miriam F. Moffatt,10 George T. O’Connor,9 Benjamin A. Raby,2
Edwin K. Silverman,2 and Scott T. Weiss2,4
Asthma, a chronic airway disease with known heritability, affects more than 300 million people around the world. A genome-wide asso-
ciation (GWA) study of asthma with 359 cases from the Childhood AsthmaManagement Program (CAMP) and 846 genetically matched
controls from the Illumina ICONdb public resource was performed. The strongest region of association seen was on chromosome 5q12
in PDE4D. The phosphodiesterase 4D, cAMP-speciﬁc (phosphodiesterase E3 dunce homolog, Drosophila) gene (PDE4D) is a regulator of
airway smooth-muscle contractility, and PDE4 inhibitors have been developed as medications for asthma. Allelic p values for top SNPs in
this region were 4.3 3 1007 for rs1588265 and 9.7 3 1007 for rs1544791. Replications were investigated in ten independent popula-
tions with different ethnicities, study designs, and deﬁnitions of asthma. In seven white and Hispanic replication populations, two
PDE4D SNPs had signiﬁcant results with p values less than 0.05, and ﬁve had results in the same direction as the original population
but had p values greater than 0.05. Combined p values for 18,891 white and Hispanic individuals (4,342 cases) in our replication pop-
ulations were 4.1 3 1004 for rs1588265 and 9.2 3 1004 for rs1544791. In three black replication populations, which had different
linkage disequilibrium patterns than the other populations, original ﬁndings were not replicated. Further study of PDE4D variantsmight
lead to improved understanding of the role of PDE4D in asthma pathophysiology and the efﬁcacy of PDE4 inhibitor medications.Introduction
Asthma (MIM 600807), a chronic respiratory disease result-
ing from the complex interaction of multiple genetic and
environmental factors, affects more than 20 million Amer-
icans and 300 million people worldwide.1,2 In candidate-
gene association and linkage studies, more than 40 genes
have been associated with asthma and replicated in at
least one independent population.3 Recently, the ﬁrst
genome-wide association (GWA) study of asthma found
that ORMDL3 (MIM 610075) variants contribute to the
risk of childhood-onset asthma,4 and its results have been
successfully replicated in at least eight populations.5–10
AnotherGWAstudy in theHutterites, a founder population
of European descent, found that CHI3L1 (MIM 601525)
variants are associated with asthma and related pheno-
types.11 Its ﬁndings were replicated with partial success in
two independent cohorts.11 The results of these studies
have added to the growing credibility of theGWAapproach
foruncoveringnovel diseasevariants incomplexdiseases.12
In this work, we describe the results of a GWA study in
which we found association between asthma and single-nucleotide polymorphisms (SNPs) in the phosphodies-
terase 4D, cAMP-speciﬁc (phosphodiesterase E3 dunce
homolog,Drosophila) gene (PDE4D [MIM 600129]). PDE4D
is a compelling asthma candidate gene because its protein
products are involved in the regulation of airway smooth-
muscle contractility.13,14
Material and Methods
Subjects
Cases were 422 non-Hispanic white subjects from CAMP, a clinical
trial that followed 1,041 asthmatic children for 4 years and nearly
80% of the original participants for 12 years.15 Stringent inclusion
criteria ensured that participants had mild to moderate asthma,
which was deﬁned as asthmatic symptoms at least twice per week
andeitheruseof asthmamedicationdailyoruseof an inhaledbron-
chodilator twiceperweek for sixormoremonthsof theyearprior to
recruitment. CAMP subjects had increased airway responsiveness,
as established by a bronchoprovocation test in which there was
20% or greater FEV1 reduction after administration of up to 12.5
mg/dl of methacholine. CAMP participants and their parents
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for family-based genetic studies, this design was underpowered for
the measurement of associations to asthma.We sought to increase
the ability to ﬁnd such associations by comparing CAMP probands
to publicly available controls. Genotype data for 1,533 white
control subjects were obtained from Illumina’s iControlDB
resource.
Genotyping and Quality Control
Genome-wide SNP genotyping for CAMP subjects, their families,
and iControlDB controls was performed on Illumina’s Human-
Hap550 Genotyping BeadChip (Illumina, Inc., San Diego, CA).
CAMP samples and markers passed stringent quality-control stan-
dards; 6,257 markers were removed as a result of low clustering
scores. Markers whose ﬂanking sequences did not map to a unique
position on the HG17 reference genome sequence were removed
(n ¼ 1,329). Further quality control was performed with PLINK
version 1.03.16 The average completion rate for each marker was
more than 99%. Monomorphic markers (n ¼ 3,790) and those
with ﬁve or more Mendel errors (n ¼ 2,445) were removed. We
assessed genotype reproducibility by plating four subjects once
on each of 14 genotyping plates. All of these replicates had at least
99.8% concordance. The average genotyping completion rate for
each subject was 99.75%.
In addition to undergoing quality-control procedures at Illumina
(Illumina, Inc., SanDiego,CA), controls from iControlDBwerepro-
cessed with equal quality-control standards as CAMP cases, except
for searches ofMendelian errors because family datawere not avail-
able. CAMP cases and iControlDB controls had 547,497 overlap-
ping SNPs that passed these initial ﬁlters.
Additional ﬁltering of subjects (cases plus controls) and SNPs
was performed with PLINK. Subjects were dropped from further
analysis for the following reasons: they were siblings of other
subjects (23 cases), more than 5% of genotype data was missing
(19 cases), there was evidence of identity by descent (IBD) with
Pi-hat > 0.01 (57 controls), or there was discordance between
reported and observed sex (three controls). SNPs were dropped
from further analysis for the following reasons: they were missing
in more than 5% of subjects (n ¼ 3,837), minor allele frequency
(MAF) was less than 1% (n ¼ 17,088), Hardy-Weinberg equilib-
rium p values among controls were less than 0.001 (n ¼ 2,046),
the missing rate in cases and controls was signiﬁcantly different
as determined by a p value less than 105 (n ¼ 6,642). Evidence
of population stratiﬁcation was present in the remaining 1,913
subjects (380 cases and 1,533 controls) and 518,230 SNPs, as indi-
cated by a genomic inﬂation factor of 1.33 obtained in PLINK from
unadjusted Chi-square values for allelic association of a subset of
28,189 independent SNPs (r2 < 0.07).
In order to control for population stratiﬁcation, we used genetic
matching (GEM).17 This approach removes genetic outliers and
matches subjects on the basis of genetic similarities derived from
eigenvector decomposition. A subset of 22,828 independent
SNPs, which all had a pairwise r2 less than 0.07 among controls
in PLINK, were selected for use in GEM. The initial matrix created
with data on the independent SNPs had three signiﬁcant eigenvec-
tors, and the initial outlier-removal step in GEM, which removed
subjects who were 6 SD or further along any of the signiﬁcant
eigenvector directions, resulted in the exclusion of three cases
and 29 controls. Next, we selected a GEM clustering coefﬁcient
of 0.01, which excluded an additional 18 cases and 658 controls
for whom distances from the case to the nearest control and
vice-versa in the eigenspace composed of the three signiﬁcant
eigenvectors was larger than the 0.01 cutoff. The genomic inﬂa-582 The American Journal of Human Genetics 84, 581–593, May 15tion factor for the remaining 1,205 subjects (359 cases and 846
controls) was 1.03, demonstrating minimal population stratiﬁca-
tion. To further verify that population stratiﬁcation among these
subjects was minimal, we used EIGENSTRAT to obtain unadjusted
Cochran-Armitage trend test and EIGENSTRAT-corrected associa-
tion statistics.18 Comparison of the corrected and uncorrected
association statistics demonstrated that uncorrected test statistics
changed minimally with further correction for population stratiﬁ-
cation. Therefore, EIGENSTRAT was not used for adjusting statis-
tics in subsequent analyses. The 1,205 subjects (359 cases, 846
controls) that were used in subsequent statistical analyses are
referred to as the CAMP/Illumina study.
Statistical Analysis
Figure 1 is an overview of our study design. First, we performed
a case-control analysis with CAMP/Illumina (Figure 1A). We
selected SNPs for further consideration by choosing a nominal
p value cutoff (13 106) based on the allelic p value distribution.
After identifying top case-control associations, we performed
family-based association tests to ensure that associations remained
in parent-offspring trios (Figure 1B). Case-control associationswere
measured in PLINK16; allelic tests were used for screening, and
Cochran-Armitage trend tests were used for comparison with
family-based studies. Family-based association statistics for 387
CAMP trios under an additive model were calculated with Golden
Helix PBAT version 6.4.0.19 Replication of association results was
attempted in ten independent populations (Figure 1C). Haplo-
view20 was used for inferring linkage disequilibrium (LD) among
SNPs from r2 measures in family data. Wemeasured joint evidence
for association across populations byusing Fisher’s combinedprob-
abilitymethod21 to combinepvalues (Figure1D). In the combining
of p values, all hypothesis tests in replication populations had one-
sided alternatives (based on the direction of the association in the
testing population) so that SNPs with association tests in opposite
directionswouldnot produce inappropriately small p values. Effect
estimates were calculated with allelic odds ratios (ORs) for case-
control data and transmitted-to-untransmitted (T:U) ratios for
family data. T:U ratios were calculated in Haploview. Summary
ORs, based on allelic ORs for case-control and population-based
studies, were estimated with the DerSimonian-Laird22 random-
effects meta-analysis approach as implemented in the rmeta
package inR.23 Power calculationswere performedwith the genetic
power calculator of Purcell S, et al.24 with a high-risk allele
frequency of 0.30, prevalence of 0.10, D-prime of 1, marker allele
frequency of 0.30, an assumption of the use of unselected controls,
and default error rates (alpha¼ 0.05, power¼ 0.80). InCAMP fami-
lies, the association between SNPs and the log-transformedmetha-
choline concentration that caused a 20% decrease in FEV1 was
measuredunder anadditivemodel via generalized estimating equa-
tions in Golden Helix PBAT version 6.4.0,19 in which adjustments
were made for age and gender.
Replication Studies
(1) B58C. The British 1958 Birth Cohort is a nationally representa-
tive sample of people who were born during one week in 1958 and
who have been followed periodically through childhood and adult
life. Blood samples obtained at a medical examination at age 44–
45 years25 were used as the basis of a DNA reference collection for
genetic case-control studies. Information on wheezing illness and
asthma was gathered through parental interviews at ages 7, 11,
and 16 years and through cohort-member interviews at ages 23,
33, and 42 years, as described in detail elsewhere.26 For this study,, 2009
Figure 1. Study Overview
(A) 359 CAMP cases and 846 Illumina controls were used in tests for the genome-wide association of individual SNPs to asthma status.
Four SNPs with p values less than 106 in a biologically plausible candidate gene and in an LD association peak were analyzed further.
(B) Using genome-wide association results of family-based statistical analysis in CAMP probands and their parents, we analyzed the four
SNPs that met the criteria described in (A). These four SNPs had p values less than 0.05.
(C) Generalizability of the findings was tested through replication attempts in ten independent populations. Numbers under each name
are cases/controls for case-control designs; affected/unaffected for population-based designs and GRAAD2; and number of trios for Costa
Rica. Data for two SNPs were available in the ten populations.
(D) Joint association analysis for the two SNPs in seven populations with similar LD patterns among the top CAMP/Illumina SNPs was
performed. Because LD patterns among the most significant SNPs were very different in black populations (red boxes), these were
analyzed separately.cases were 821 individuals who had asthma or wheezing by age 16
and controls were 2,469 individuals who did not have asthma or
wheezing by the last cohort interview. Cases and controls were
determined to be white by self-report as adults and by school
medical examinations in childhood. Genotype data was obtained
with the Illumina HumanHap550 Genotyping BeadChip. Associa-
tionbetween individual SNPsandasthmastatuswasmeasuredwith
the Cochran-Armitage trend test implemented in R.23
(2) CHOP. North Americanwhite children of Northern European
descent were recruited at the Children’s Hospital of Philadelphia
(CHOP) between 2006 and 2008.5 Cases included 569 patients
with physician-diagnosed persistent asthma necessitating regular
administrationof inhaledglucocorticoidmedications for symptom
control. Disease severity matched steps 2–6 as reported in the
Asthma Expert Panel-3 guidelines.27 Controls included 2,136
subjectswhowere determined to havenohistory of asthmaor reac-
tive airway disease by questionnaire and who had never been
prescribed asthmamedications according to their medical records.
Mean age of caseswas 8.75 5.7 SDyears, and 58.7%weremale; the
mean age of the controls was 8.45 6.1 SD years, and 49.4% were
male. Genome-wide genotyping was performed at the Center for
Applied Genomics on the Illumina HumanHap550 Genotyping
BeadChip.Patients andcontrolswere screenedat ancestry-informa-
tivemarkers, and the corresponding genomic inﬂation factor, 1.07,
demonstratedminimal backgroundpopulation stratiﬁcation. Asso-
ciation between individual SNPs and asthma status was measured
with the Cochran-Armitage trend test implemented in PLINK.The Am(3) CHOP2. African American children were recruited on the
basis of criteria similar to those used for CHOP subjects.5 Cases
included 1,456 patients with physician-diagnosed persistent
asthma. Controls included 1,973 subjects who were determined
to havenohistory of asthmaor reactive airway disease by question-
naire and who had never been prescribed asthma medications
according to their medical records. The mean age of cases was
7.55 5.7 SD years, and 57% were male; the mean age of controls
was6.755.2SDyears, and49%weremale.Genome-widegenotyp-
ing was performed at the Center for Applied Genomics on the Illu-
minaHumanHap550Genotyping BeadChip. Patients and controls
were screened at ancestry-informative markers, and the corre-
sponding genomic inﬂation factor, 1.1, demonstrated minimal
background population stratiﬁcation. Association between indi-
vidual SNPs and asthma status was measured with the Cochran-
Armitage trend test implemented in PLINK.
(4) CHOP3. This cohort consisted of 365white caseswhowere of
NorthernEuropeandescent andwhowere recruited atCHOP.Cases
hadasthmaaccording tophysiciandiagnosis andusedbeta-agonist
medications. Controls consisted of 690 white subjects who were
recruited at CHOP, who were of Northern European descent, and
who were determined to have no history of asthma or reactive
airway disease by questionnaire and had never been prescribed
asthma medications according to their medical records. CHOP
cases and controls used in this cohort did not overlap with those
in the CHOP population described in (2). Genome-wide genotyp-
ing was performed at the Center for Applied Genomics on theerican Journal of Human Genetics 84, 581–593, May 15, 2009 583
Illumina HumanHap550 Genotyping BeadChip. Subjects were
screened at ancestry-informative markers, and the corresponding
genomic inﬂation factor, 1.05, demonstratedminimal background
population stratiﬁcation. Associationbetween individual SNPs and
asthma status wasmeasured with the Cochran-Armitage trend test
implemented in PLINK.
(5) CHS. The Children’s Health Study (CHS) is an ongoing
cohort study in Southern California and investigates both genetic
and environmental factors related to childhood asthma and lung
function growth.28 The CHS GWAS was based on a nested case-
control sample of 769 asthmatics and 1,007 controls selected
from within the cohort. All subjects in this GWAS sample were
either Hispanic white (n ¼ 817) or non-Hispanic white (n ¼
959). On the basis of questionnaire responses, children were char-
acterized as having doctor-diagnosed asthma at study entry or
during active follow-up (cases) or as never having a diagnosis of
asthma (controls). Buccal cells were collected from study subjects,
and genotyping was performed by the USC Genomics Center with
the Illumina HumanHap550 Genotyping BeadChip. Association
between individual SNPs and asthma status was measured in R23
via logistic regression with additive genetic models; adjustments
were made for age, sex, Hispanic status, community, and q factors
obtained from STRUCTURE.29
(6) FHS. The Framingham Heart Study (FHS) conducted clinical
examinations that include spirometry and collection of smoking
history data on three generations of white adults of European
descent, and research participants provided DNA samples that
have recently been genotyped for genome-wide association
studies.30,31 Asthma was classiﬁed on the basis of self-report of
physician diagnosis, and according to this deﬁnition, there were
961 cases and 6,516 controls. In FHS subjects, genotyping was per-
formed with the Affymetrix GeneChip Human Mapping 500K
Array Set and an additional Affymetrix 50K Array (HuGeneFocu-
sed50K). Because data from these assays did not include that of
the most associated SNPs in the CAMP/Illumina analysis, those
genotypes were inferred via imputation with the Markov Chain
Haplotyping software (MaCH).32 The ratio of the empirically
observed dosage variance to the expected (binomial) dosage vari-
ance for these imputed SNPs was greater than 0.9, indicating
good quality of imputation. Association to asthma was measured
with logistic regression models, in which robust variance was esti-
mated via generalized estimating equations with each pedigree as
a cluster; adjustments were made for age, former smoking, current
smoking, pack-years, sex, BMI, and membership in one of the
three recruited generations. The genomic inﬂation factor for the
imputed genome-wide results was 1.048, indicating minimal pop-
ulation stratiﬁcation.
(7) MRC-A/UK-C. Study subjects include 378 children from the
MRC-A cohort (265 cases and 113 controls) and 434 nonasthmatic
white UK controls (UK-C) studied according to the same proto-
cols.4 The MRC-A cohort was recruited through a proband with
severe childhood onset asthma and consisted of 295 sibling pairs,
11 half-sibling pairs, and three singletons. Asthmatic subjects were
deﬁned as those who gave a positive response to the question,
‘‘Has your doctor ever told you that you have asthma’’? Addition-
ally, probands were determined to have severe asthma if they had
step 3 or worse asthma according to British Thoracic Society guide-
lines (i.e., if they were on high-dose inhaled steroids or if they were
on low-dose inhaled steroids and a long-acting beta-agonist). In
MRC-A/UK-C subjects, genotyping was performed with the Illu-
mina Sentrix HumanHap300 BeadChip.4 In MRC-A/UK-C
subjects, association between individual SNPs and asthma status584 The American Journal of Human Genetics 84, 581–593, May 15was measured via logistic regression models, and robust sandwich
estimation of the variance as implemented in the Stata logit func-
tion was used for modeling the clustering of siblings’ genotypes.4
(8) Costa Rica. This cohort consists of 592 probands from the
Genetics of Asthma in Costa Rica Study, which is comprised of
Costa Rican schoolchildren with asthma and their parents.33,34
Children had a high probability of having at least six great-grand-
parents born in the Central Valley of Costa Rica and were deﬁned
as having asthma if they had a doctor’s diagnosis of asthma and at
least two respiratory symptoms or asthma attacks in the year prior
to enrollment in the study. Methacholine-challenge testing was
performed in probands as described previously.35 Genotype data
intended to replicate CAMP/Illumina ﬁndings was obtained with
Taqman real-time PCR with an ABI Prism 7900 machine (Applied
Biosystems, Foster City, CA). Standard PCR conditions, as recom-
mended by the manufacturer, were used. Family-based association
statistics for asthma affection status under an additive model were
calculated with Golden Helix PBAT version 6.4.0.19 The associa-
tion between SNPs and the log-transformed methacholine dose
that caused a 20% decrease in FEV1 was measured under an addi-
tive model via generalized estimating equations in PBAT; adjust-
ments were made for age and gender. T:U ratios of alleles were
calculated in Haploview.20
(9) GRAAD1. The Genomic Research on Asthma in the African
Diaspora (GRAAD) African American cohort consisted of 447
asthma cases and 459 nonasthmatic controls. Asthmatic subjects
were deﬁned as those who had both a reported history of asthma
and a history of physician-diagnosed asthma (past/current). All
controls except 50 were determined to be negative for a history
of asthma; asthma status on the 50 controls participating in
a study on the genetics of human pigmentation was unknown.36
Genotyping was performed with the Illumina HumanHap650Y
BeadChip. Association between individual SNPs and asthma status
was measured with the Cochran-Armitage trend test in PLINK.
(10) GRAAD2. The GRAAD Barbados cohort consisted of 929
subjects (355 asthmatics) from 163 families. These African Carib-
bean asthma probands and their nuclear and extended family
members were recruited in Barbados through referrals at local poly-
clincs or the Accident and Emergency Department of the Queen
Elizabeth Hospital.37 Asthmatic subjects were deﬁned as those
who had both a reported history of asthma and a documented
history of physician-diagnosed asthma (past/current), plus
a history of wheezing without an upper-respiratory infection
(URI) or two out of four hallmark symptoms (wheezing with
a URI, cough without a URI, shortness of breath, and tightness
in the chest). Genotyping was performed with the Illumina
HumanHap650Y BeadChip. Family-based association statistics
under an additive model were calculated with FBAT.38 T:U ratios
of alleles were calculated in Haploview.20
Each study was approved by the institutional review board of
the corresponding Institution, which ensured that all procedures
were in accordance with the ethical standards of the responsible
committee on human experimentation. Informed consent was
obtained for all study participants.
Results
After QC ﬁlters, 518,230 SNPs genotyped in 359 CAMP
cases and 846 Illumina controls were used for testing the
association of SNPs to asthma. There was little evidence
of population stratiﬁcation in these subjects, who were, 2009
Figure 2. EIGENSTRAT-Corrected Association Statistics
CAMP/Illumina GWA statistics as adjusted by EIGENSTRAT are
highly correlated (r2 ¼ 0.98) with unadjusted statistics, demon-
strating minimal residual population stratification.
Figure 3. Quantile-Quantile Plot
Comparison of CAMP/Illumina allelic p values to those expected for
a null distribution. Deviation of measures at the tail may indicate
true associations between some SNPs and asthma.matched via GEM, as indicated by a genomic inﬂation
factor of 1.03. Furthermore, EIGENSTRAT-corrected associ-
ation statistics were highly correlated (r2 ¼ 0.98) with
unadjusted statistics (Figure 2). A quantile-quantile plot
comparing allelic-association p values to those expected
for a null distribution revealed some deviation of measures
at the tail, indicating that true associations between SNPs
and asthma may be present (Figure 3). The top ﬁve SNPs,
whose p values deviated most from the distribution of all
p values and had nominal p values less than 1 3 106,
were located on Chromosomes 5 and 8 (Table 1; Figure 4).
Initially, we substantiated case-control results by
comparing them to family-based statistical analysis by
using CAMP probands and their parents. The top case-
control SNPs had signiﬁcant (i.e., < 0.05) PBAT additive-
model p values in the CAMP families, although they did
not rank highest on the list (Table 2). Instead, they ranked
between positions 2,947 and 10,852 out of more than
500,000 SNPs. Comparison of CAMP-family T:U ratios to
allelic ORs obtained in CAMP/Illumina reveals that the
effect estimate is consistent but smaller in the family-based
analysis. Although the trio results are not entirely indepen-
dent of the CAMP/Illumina results because CAMP
probands were used for both analyses, they add credibility
to the CAMP/Illumina ﬁndings. We proceeded by attempt-
ing to replicate the chromosome 5, rather than chromo-
some 8, SNP ﬁndings because (1) these four SNPs, which
are in nearly complete LD with each other, are in an LD
peak, whereas other SNPs are more weakly associated
with asthma (Figure 5), and (2) the chromosome 5 LD
peak is in PDE4D, which is a plausible biological candidate
gene for asthma because it is an important regulator of
airway smooth-muscle contractility.13,14The AmThe generalizability of CAMP/Illumina chromosome 5
ﬁndings was tested by replication attempts in ten indepen-
dent populations with diverse ethnicities. LD patterns of
the top SNPs were obtained for family-based populations
and for European American (CEU), Chinese and Japanese
(CHBþJPT), and Yoruban (YRI) HapMap39 populations
(Figure 6). Because Costa Rica had LD patterns in the top
PDE4D SNPs that were very similar to those of CAMP
and CEU, the Hispanic populations were analyzed in
conjunction with the white populations. However,
because the LD patterns in YRI and GRAAD2 were
extremely different from those of other populations, the
black populations were analyzed separately. We focused
our results on two PDE4D SNPs that had genotype data
in all populations.
Among white and Hispanic populations, all replication
attempts had effects in the same direction as CAMP/Illu-
mina (Table 3). Two of these (FHS, CHOP) had individual
p values less than 0.05, and ﬁve (CHS, CHOP3, Costa
Rica, B58C and MRCA/UKC) had p values that were not
less than 0.05. The combined p values for 18,891 white
and Hispanic individuals (4,342 cases) in these replication
populations were 4.13 104 for rs1588265 and 9.23 104
for rs1544791. Overall, if CAMP/Illumina are included in
the joint calculation, the p values were 2.5 3 108 for
rs1588265 and 1.2 3 107 for rs1544791. Summary ORs
for the effects of these two SNPs in case-control and popu-
lation-based studies were 0.85 (95% conﬁdence interval
[CI]: 0.77, 0.93) among all populations and 0.88 (95% CI:
0.83, 0.94) among replication populations for rs1588265,
and they were 0.85 (95% CI: 0.78, 0.94) among all popula-
tions and 0.89 (95% CI: 0.84, 0.94) among replication
populations for rs1544791 (Figure 7). The Costa Rica effecterican Journal of Human Genetics 84, 581–593, May 15, 2009 585
Table 1. Top 5 SNPs that Were Individually Associated with Asthma According to Allelic-Model p Values in CAMP/Illumina GWA
Study
SNP CHR BP HWE p Value Minor Allele MAF Cases MAF Controls Allelic p Value OR (95% CI)
rs2548659 5 59419643 0.45 G 0.23 0.34 1.5 3 107 0.58 (0.48–0.71)
rs1588265 5 59405551 0.68 G 0.23 0.34 4.3 3 107 0.60 (0.49–0.73)
rs983280 5 59480894 0.63 G 0.23 0.34 4.8 3 107 0.60 (0.49–0.73)
rs11778371 8 27375822 1 A 0.09 0.04 8.1 3 107 2.32 (1.65–3.27)
rs1544791 5 59474839 0.63 A 0.24 0.34 9.7 3 107 0.61 (0.54–0.78)
Minor allele corresponds to Illumina’s top-strand convention. CHR: chromosome. BP: base pairs along corresponding chromosome. HWE: Hardy-Weinberg
equilibrium. MAF: minor-allele frequency. OR: odds ratio.estimate, which was a T:U ratio, was not amenable to being
combinedwith the ORs in themeta-analysis. In three black
replication populations, original ﬁndings were not repli-
cated (Table 4). Association of rs1588265 and rs1544791
to airway responsiveness was measured in CAMP and
Costa Rica families, the only subjects with methacholine-
challenge test data available, and neither group had signif-
icant p values (Table 5).
The association between SNPs and asthma at variants
reported tomodify asthma risk in previous GWA studies4,11
was measured in CAMP/Illumina (Table 6).
Discussion
The CAMP population was designed for and has often been
used infamily-basedcandidate-geneassociationstudies.40–42
Recently, GWA data has been acquired for a portion of the
cohort, namely, the white probands and their parents.
Although the intention behind gathering these data was to
conduct family-based genetic-association studies, prelimi-
naryanalysis found that thedataweregravelyunderpowered
for the measurement of associations to asthma (data not
Figure 4. GWA Results for CAMP/Illumina
The x axis denotes the position along each chromosome. The y axis
denotes Log10(P), corresponding to allelic p values. Five SNPs
have nominal p values less than 1 3 106 (shown in red); four
are located on chromosome 5, and one is on chromosome 8.586 The American Journal of Human Genetics 84, 581–593, May 15shown).We sought to increase the ability toﬁndassociations
to asthma by creating a case-control study with CAMP
probands. The availability of population controls provided
by Illumina through the iControlDB resource and the design
of programs such as GEM to genetically match such popula-
tions to cases has made our analysis possible. Although it is
optimal to design case-control genetic studies by carefully
selecting cases and controls at the outset, gathering the
same data for all subjects, and ensuring that controls do
not share the same phenotype as the cases, the approach
we have used is an alternative that may yield useful results
for population designs that lack controls. In ongoing work,
we are more thoroughly comparing the CAMP/Illumina
results to the CAMP family-based ones.
In CAMP/Illumina, the top ﬁve p values, which are all
smaller than our nominal cutoff of 1 3 106, do not reach
genome-wide signiﬁcance as deﬁned by a traditional Bon-
ferroni correction threshold near 1 3 107 (¼ 0.05/
500,000). Despite not reaching this threshold, we pro-
ceeded to test for replication of PDE4D SNPs because (1)
CAMP/Illumina was composed of relatively few subjects
for a GWA study and therefore, although better powered
than the family-based design, was not of high enough
power to measure effect sizes near 1.0, which are expected
for complex diseases12, and (2) PDE4D is a highly plausible
candidate gene, which adds to the credibility of the associ-
ation result. If the empirical values for CAMP/Illumina
genotype-relative risks (i.e., 0.7 for heterozygotes and 0.5
Table 2. Family-Based Analysis of Top PDE4D SNPs from
CAMP/Illumina GWA Study in CAMP Trios
SNP CHR
PBAT Additive
Model p Value
Family-Based
Analysis Ranking
Minor-Allele
T:U Ratio
rs2548659 5 0.006 3,122 0.73
rs1588265 5 0.009 5,000 0.75
rs983280 5 0.019 10,253 0.77
rs11778371 8 0.006 2,947 1.76
rs1544791 5 0.020 10,852 0.77
Family-based analysis ranking of SNPs among the GWA set based on PBAT
additive-model p values shows that the SNPs were not highest on the
list, as they were in CAMP/Illumina. The minor-allele T:U ratio demonstrates
that the direction of the effect was equal to, but the magnitude was lower
than, that measured in CAMP/Illumina., 2009
for minor-allele homozygotes) are reﬂective of a true
process, then despite its small size, CAMP/Illumina has
a power of 0.96 to detect the effect measured. If, however,
the true effects are more modest and closer to those
measured in many of the replication populations (i.e.,
0.82–0.95), then CAMP/Illumina would have nearly no
Figure 5. Region of Association of
PDE4D SNPs to Asthma in CAMP/Illumina
GWAS
(A) The x axis denotes the position
along chromosome 5. The y axis denotes
–Log10(P), corresponding to allelic p values.
LD between the SNP with the lowest p value
(rs1544791) to each SNP in the plot is
denoted in colors (red, strong LD; orange,
moderate LD; and yellow, weak LD).
(B) Corresponding location of genomic
sequences available in the UCSC genome
browser.
power to measure the association, as
reﬂected by power values as low as
0.10–0.25. The combined p values of
our replication populations were less
than 0.05, but only two out of seven
of these populations have individual
p values less than 0.05. As was the
case for CAMP/Illumina, most of the
populations used in this study are
individually too small to be powered
to ﬁnd associations with SNPs whose
effect sizes are in the range expected
for a complex disease. Although there
are many subjects overall, combining
the populations to make overall
conclusions about asthma is subject
to error because of the different recruitment criteria of
each study, the different study designs used (e.g., family-
based versus case-control designs), and the wide range of
geographic and environmental differences among popula-
tions. Even though PDE4D is a highly plausible asthma
candidate gene, in the absence of biological evidence, weFigure 6. Linkage Disequilibrium among Top
Chromosome 5 CAMP/Illumina SNPs
Panels are for six family-based populations: CAMP,
Costa Rica, GRAAD2, HapMap European American
(CEU), Chinese and Japanese (CHBþJPT), and
Yoruban (YRI). Values in boxes are r2 measures
on a decimal scale (i.e., 97 represents r2 ¼
0.97). Boxes without numbers have r2 ¼ 1. The
pattern of LD is very similar in CAMP, Costa Rica,
and CEU. There are moderate differences in LD
between CHBþJPT and each of the CAMP, Costa
Rica, and CEUpopulations. The patterns in GRAAD2
and YRI are extremely different from those of the
other populations. Genotype data for three of
the four SNPs were available in Costa Rica. Geno-
type data for two of the four SNPs were available
in GRAAD2.
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cannot exclude the possibility that the associations we
measured were due to chance alone.
PDE4D, a gene whose sequence spans a 1.5Mb region on
chromosome 5q12, encodes several isoforms that play
a role in tailoring cyclic adenosine monophosphate
(cAMP) signaling.43,44 Due to the ubiquitous role of
cAMP signaling in all cell types, it is likely that polymor-
phisms of PDE4D inﬂuence a wide variety of diseases.
Table 3. Association Results of PDE4D SNPs in Eight Independent Populations
Study
Sample
Size Analysis
rs1588265 rs1544791
Replication
MAF
Affected
MAF
Unaffected
Effect
Estimate p Value
MAF
Affected
MAF
Unaffected
Effect
Estimate p Value
Case-Control Designs
CAMP/Illumina 359; 846 Trend
test
0.23 0.34 0.60
(0.48–0.71)
5.10 3
107
0.24 0.34 0.61
(0.54–0.78)
1.20 3
106
Initial finding
B58C 821; 2469 Trend
test
0.3 0.31 0.93
(0.82–1.05)
0.12 0.3 0.31 0.94
(0.84–1.07)
0.18 Nonreplication,
same direction
CHOP 569; 2136 Trend
test
0.28 0.32 0.85
(0.73–0.98)
0.016 0.29 0.32 0.86
(0.75–0.99)
0.024 Replication
CHOP3 365; 690 Trend
test
0.31 0.32 0.95
(0.78–1.15)
0.29 0.3 0.32 0.91
(0.75–1.10)
0.27 Nonreplication,
same direction
CHS 769; 1007 LR 0.28 0.3 0.86
(0.70–1.08)
0.07 0.28 0.31 0.82
(0.65–1.02)
0.07 Nonreplication,
same direction
Population-Based Designs
FHS 961; 6516 LR 0.26 0.29 0.86
(0.76–0.97)
0.006 0.26 0.29 0.85
(0.75–0.96)
0.006 Replication
MRC-A/UK-C 265; 547 LR 0.29 0.32 0.87
(0.67–1.13)
0.14 0.3 0.32 0.91
(0.70–1.18)
0.24 Nonreplication,
same direction
Family-Based Designs
Costa Rica 353/355 PBAT 0.32 0.33 0.9 0.12 0.32 0.33 0.91 0.12 Nonreplication,
same direction
Sample sizes refer to the number of cases; controls in the case-control designs, affected; unaffected individuals in the population-based designs, and the
number of informative families for SNPs rs1588265 and rs1544791, respectively, in the family-based designs. In the Analysis column, the method used for
obtaining p values is described: ‘‘Trend test’’ refers to the Cochran-Armitage trend test; ‘‘LR’’ to logistic regression; and ‘‘PBAT’’ to the pedigree-based asso-
ciation test. Logistic regressions and PBAT used additive models. MAF unaffected in Costa Rica is the parental allele frequency. Effect estimates are as
follows: allelic OR and corresponding 95% CI for studies that used trend tests; OR calculated from beta coefficient and corresponding 95% CI for studies
that used LR models; and minor-allele T:U ratio for family-based designs. The overall p values for the independent populations were 4.1 3 104 for
rs1588265 and 9.2 3 104 for rs1544791.
Figure 7. Summary ORs for Effects of PDE4D SNPs in Seven Populations
(A)SummaryORs for rs1588265are0.85 (95%CI: 0.77, 0.93) amongall populations and0.88 (95%CI: 0.83, 0.94)among replicationpopulations.
(B) Summary ORs for rs1544791 are 0.85 (95% CI: 0.78, 0.94) among all populations and 0.89 (95% CI: 0.84, 0.94) among replication
populations. Boxes are at the mean OR for each study, and their size is proportional to study size. Gray bars represent 95% CIs. The
summary OR (diamond) was estimated with the DerSimonian-Laird random-effects model.588 The American Journal of Human Genetics 84, 581–593, May 15, 2009
Table 4. Association Results of PDE4D SNPs in Three Black Populations
Population Design
Sample
Size Analysis
rs1588265 rs1544791
MAF
Affected
MAF
Unaffected
Effect
Estimate p Value
MAF
Affected
MAF
Unaffected
Effect
Estimate p Value
CHOP2 Case-control 1456, 1973 Trend test 0.22 0.22 1.00
(0.89, 1.12)
0.50 0.36 0.34 1.09
(0.99, 1.20)
0.95
GRAAD1 Case-control 447, 459 Trend test 0.20 0.21 0.94
(0.75, 1.19)
0.22 0.35 0.35 1.00
(0.83–1.22)
0.38
GRAAD2 Family-based 77/88 FBAT 0.20 0.23 1.16 0.88 0.38 0.38 1.14 0.84
In the analysis column, ‘‘trend test’’ refers to the Cochran-Armitage trend test, and ‘‘FBAT’’ refers to the family-based association test. FBAT used additive
models. MAF unaffected in GRAAD2 is the allele frequency among all unaffected family members. Sample size in GRAAD2 is that of informative families for
each SNP. Effect estimates are as follows: allelic OR and corresponding 95% CI for studies that used trend tests and T:U ratio of the minor allele for GRAAD2
trios.Previous studies have reported that polymorphisms of this
gene are associated with stroke (MIM 601367), COPD
(MIM 606963), and bone mineral density (MIM 601884).
The initial report that a PDE4D haplotype consisting of
one SNP (rs12188950) and a microsatellite (AC008818-1)
were associated with stroke45 has been followed by at least
15 studies making similar inquiries.44,46 Because these
studies, which differ considerably in stroke subtypes and
genotypic polymorphisms investigated, have provided
varying results for associations between PDE4D and stroke
in populations of various origins, there is currently no
conclusive evidence that PDE4D variants are associated
with stroke.44,46 A small study reported the associations
of one PDE4D SNP (rs829259) and a haplotype consisting
of one PDE4D (rs10075508) and one interleukin 13 SNPs
to COPD in a Japanese population, but neither association
replicated in an Egyptian population.47 One PDE4D SNP
(rs1498608) was found to be associated with bone mineral
density in women of a discovery and independent popula-
tions, whereas a second independent cohort of women
had an association in the opposite direction.48 To the
best of our knowledge, PDE4D polymorphisms have not
been previously associated with asthma.
The importance of PDE4D in airway contractility has
been demonstrated in studies showing that it is the
predominant phosphodiesterase expressed in mouse lung
and that PDE4D knockout mice have a complete absence
of airway response to methacholine.13,14 Clinical trials
Table 5. Family-Based Analysis of Airway Responsiveness
Association to PDE4D SNPs in CAMP and Costa Rica Trios
SNP Minor Allele CAMP p Value Costa Rica p Value
rs1588265 G 0.42 0.74
rs1544791 A 0.38 0.74
Association between SNPs and the log-transformed methacholine concen-
tration (in CAMP) and dose (in Costa Rica) that caused a 20% decrease in
FEV1 were measured under an additive model, in which adjustments were
made for age and gender. No significant associations were found. The nega-
tive sign indicates association direction.The Amhave tested PDE4 inhibitors for asthma and COPD treat-
ment.49,50 Most PDE4 inhibitors reduce airway responsive-
ness and the recruitment of eosinophils to airways, two
characteristic features of asthma.49,50 We found that four
PDE4D SNPs were associated with asthma in a GWA study
of 359 CAMP probands and 846 publicly available Illu-
mina controls. Two of these SNPs had allelic p values of
4.3 3 107 (rs1588265) and 9.7 3 107 (rs1544791). After
attempts to replicate the initial CAMP/Illumina ﬁndings in
seven white and Hispanic independent populations,
combined p values in the replication populations were
4.1 3 104 (rs1588265) and 9.2 3 104 (rs1544791).
Including CAMP/Illumina in the joint calculation resulted
in overall p values of 2.5 3 108 for rs1588265 and 1.2 3
107 for rs1544791.
Based on comparisons with the PDE4D sequence
reported in the paper originally associating SNPs to
stroke,45 the PDE4D SNPs associated to asthma are located
near the 50 end of PDE4D, as was the SNP originally associ-
ated with stroke, but more than 340 Kb away from it in the
30 direction,whereas the asthmaPDE4D SNPs aremore than
1Mbaway from the SNPs reported to be associated toCOPD
andbonemineral density,which are at the 30 endofPDE4D.
The top four CAMP/Illumina PDE4D SNPs are located
between two exons, referred to asD7-2 andD7-3 inGretars-
dottir et al.45, whereas the SNPs in moderate LD with
them span these exons (Figure 5). The D7-2 and D7-3
exons are part of a long-form splice variant of PDE4D.
Based on another PDE4D sequence, RefSeq version
NM_001104631.1, the region of highest association is
upstream of the 50 UTR. If the association involving these
SNPs is truly indicative of a process that affects asthma,
then theycouldbe in linkagedisequilbriumwitha sequence
variant that affects the function or transcription of a partic-
ular PDE4D isoform. For instance, a PDE4D variant could
result in a version of the protein that preferentially
constricts airway smooth-muscle cells, leading to asthma.
Alternatively, a sequence variant could lead to preferential
transcription of a PDE4D isoform that is more effective at
constricting airway smooth-muscle cells, thereby leading
to asthma. Understanding the biological role that theseerican Journal of Human Genetics 84, 581–593, May 15, 2009 589
Table 6. Attempted Replication of GWAS Results Initially Reported by Moffatt et al.4 for Chromosome 17 and Ober et al.11 for
Chromosome 1 in CAMP/Illumina
SNP CHR BP
Initial Report
CAMP/Illumina p ValuePrimary GWA Study p Value Replication Study p Value
rs9303277 17 35229995 1.58 3 109 1.58 3 103 1.03 3 102
rs11557467 17 35282160 7.94 3 1010 7.94 3 104 6.03 3 103
rs8067378 17 35304874 1.00 3 109 6.77 3 103
rs2290400 17 35319766 1.58 3 1010 6.31 3 104 4.87 3 103
rs7216389 17 35323475 1.00 3 1010 7.94 3 104 1.60 3 103
rs4795405 17 35341943 2.00 3 109 2.51 3 104 7.17 3 104
rs8079416 17 35346239 6.31 3 109 1.26 3 102 1.28 3 102
rs3894194 17 35375519 2.00 3 108 6.31 3 102 7.69 3 103
rs3859192 17 35382174 5.01 3 108 3.98 3 101 2.79 3 103
rs946263 1 201432004 0.008 0.31
SNPs shown are those that were successfully genotyped and passed QC filters in CAMP/Ilumina. The Moffatt et al.4 SNPs had the same effect direction as that
initially reported (data not shown) and had significant p values (<0.05). The Ober et al.11 result did not replicate.associations may play in asthma will be challenging
because of the large size of PDE4D (1.5 Mb) and the variety
of PDE4D isoforms. Furthermore, as experiments in mice
suggest, the cells where PDE4D variants are most likely
to play an important role are airway smooth-muscle cells.
Obtaining and performing experiments in such cells in
humans is particularly challenging. Nonetheless, relating
our speciﬁc PDE4D polymorphisms to biological function
is critical for corroborating our association results and
potentially increasing our knowledge of asthma patho-
physiology and of the heterogeneity in efﬁcacy of PDE4
inhibitor medications.
The observed effects corresponding to the PDE4D SNPs
associated with asthma are small (Table 3). The summary
ORs in all of the white and Hispanic populations, 0.85
(95% CI: 0.77, 0.93) for rs1588265 and 0.85 (95% CI:
0.78, 0.94) for rs1544791, reveal an overall protective effect
of the minor alleles (Figure 7). The effect sizes measured in
CAMP/Illumina, 0.60 (95% CI: 0.48-0.71) for rs1588265
and 0.61 (95% CI: 0.54-0.87) for rs1544791, were much
smaller than those of the independent populations, which
have overall ORs of 0.88 (95% CI: 0.83, 0.94) for
rs1588265 and 0.89 (95% CI: 0.84, 0.94) for rs1544791.
One important distinction between CAMP/Illumina and
each of the other populations that could partially account
for the difference in effect estimates is that the selection of
CAMP cases included a methacholine-challenge test,
whereas most other cases were selected on the basis of self-
reported or doctor-diagnosed asthma only. Because
PDE4D is involved in airway responsiveness and increased
airway responsiveness was a selection criterion for CAMP
participants, it is likely that the CAMP/Illumina population
was biased toward the association of variants related to this
phenotype. One could test this hypothesis by measuring
the association of the PDE4D variants to airway responsive-
ness directly. Among the populations used, measures of
airway responsiveness are available in CAMP and Costa
Rica probands only. Family-based association analyses in
CAMP and Costa Rica did not produce statistically signiﬁ-590 The American Journal of Human Genetics 84, 581–593, May 15cant results for airway responsiveness in either of these
populations (Table 5). In CAMP, the minor alleles seem to
be associated with less airway responsiveness (i.e., higher
concentration of methacholine required for 20% drop in
FEV1), which is expected for subjects with less severe
asthma and is consistent with our ﬁnding that these SNPs
have aprotective effect in asthmaaffection status.However,
the Costa Rica results have an opposite trend. These
outcomes do not support our hypothesis that PDE4D vari-
ants are directly associated with airway responsiveness,
but they are not sufﬁcient to disprove it. Ideally, we would
be able to test for the association of airway responsiveness
over a range that is typical of both asthmatics and nonasth-
matics. Neither withCAMPnor Costa Rica are we able to do
this. Furthermore, becauseCAMPprobandswere selected to
have hyperresponsiveness, we are unable to measure the
association to airway responsiveness over a range that is
reﬂective of all asthmatics inCAMP families. This illustrates
a disadvantage of using unselected controls and comparing
them tomore thoroughly phenotyped cases: we are unable
to test all of the phenotypes available in cases in the case/
control design. In future studies, we hope to obtain a popu-
lation in which we can more carefully test whether PDE4D
variants are associated with airway responsiveness.
Three black populations were analyzed separately from
thewhite andHispanic populations because the LD pattern
among the top PDE4D SNPs was different in these three
populations (Table 4). TheCAMP,Costa Rica, andCEUpop-
ulations had very similar LD patterns in this region, which
makes the information at any of the top four PDE4D SNPs
nearly redundant (Figure 6). In contrast, the GRAAD2 and
YRI LD patterns demonstrate that information at each of
the four PDE4D SNPs is nearly independent of the others.
The results from the two PDE4D SNPs that are available
for the three black populations are therefore not informa-
tive about the two nongenotyped SNPs. This suggests that
the two genotyped SNPs do not directlymodify the asthma
phenotype in any of the populations but rather that they
are in LD with variants that directly modify asthma, 2009
susceptibility. More extensive genotyping may help in the
determination of whether other SNPs in PDE4D are associ-
ated with asthma, especially among black populations.
In addition to studying top CAMP/Illumina SNPs, we
attempted to replicate ﬁndings from previous asthma
GWA studies. Speciﬁcally, we measured association
between asthma and ORMDL34 and CHI3L111 variants by
looking at SNPs that passed QC ﬁlters in CAMP/Ilumina.
Nine of the original ORMDL3 SNPs reported by Moffatt
et al.4 were signiﬁcant in CAMP/Illumina (p value < 0.05),
whereas one CHI3L1 SNP reported by Ober et al.11 did not
replicate (Table 6). These results further strengthen the
hypothesis that ORMDL3 variants, or those in LD to them,
are related to asthma susceptibility. Further genotype data
are necessary to allow a more deﬁnitive statement about
whether the Ober et al.11 ﬁndings hold in CAMP/Illumina.
In summary, we have found in a GWA study that SNPs in
PDE4D seem to be associated with asthma, as indicated by
allelic p values of 4.33 107 for rs1588265 and 9.7 3 107
for rs1544791. Combined p values across seven white and
Hispanic independent populations were 4.1 3 104 for
rs1588265 and 9.2 3 104 for rs1544791, suggesting that
further study of PDE4D may lead to improved under-
standing of its role in asthma pathophysiology and the
efﬁcacy of PDE4 inhibitor medications.
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